Endonovo Therapeutics (ENDV) Change in Cash (2018 - 2023)
Endonovo Therapeutics has reported Change in Cash over the past 12 years, most recently at -$32602.0 for Q3 2023.
- Quarterly results put Change in Cash at -$32602.0 for Q3 2023, down 240.9% from a year ago — trailing twelve months through Sep 2023 was -$23139.0 (down 232.93% YoY), and the annual figure for FY2022 was -$85838.0, down 218.37%.
- Change in Cash for Q3 2023 was -$32602.0 at Endonovo Therapeutics, down from $21660.0 in the prior quarter.
- Over the last five years, Change in Cash for ENDV hit a ceiling of $489053.0 in Q2 2019 and a floor of -$542493.0 in Q3 2019.
- Median Change in Cash over the past 5 years was -$2673.0 (2020), compared with a mean of -$19955.3.
- Peak annual rise in Change in Cash hit 1867.19% in 2019, while the deepest fall reached 6359.5% in 2019.
- Endonovo Therapeutics' Change in Cash stood at $13856.0 in 2019, then decreased by 21.79% to $10837.0 in 2020, then soared by 640.09% to $80204.0 in 2021, then crashed by 128.73% to -$23041.0 in 2022, then plummeted by 41.5% to -$32602.0 in 2023.
- The last three reported values for Change in Cash were -$32602.0 (Q3 2023), $21660.0 (Q2 2023), and $10844.0 (Q1 2023) per Business Quant data.